Calico Life Sciences, backed by Alphabet, has secured exclusive global rights (outside China) to Mabwell Bioscience’s IL-11 targeting monoclonal antibody 9MW3811 in a deal worth up to $596 million including $25 million upfront. The clinical-stage asset is in phase 1 trials for idiopathic pulmonary fibrosis and related age-associated diseases. The licensing extends Calico’s pipeline targeting cytokine IL-11, reinforcing its focus on aging-related interventions. Mabwell retains development rights in Greater China, with plans for U.S. clinical trials pending FDA approval. This partnership integrates Mabwell’s expertise with Calico’s aging biology platform and existing collaborations with AbbVie and the Broad Institute.